(Q53579533)

English

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

scientific article published in February 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

10

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

11

object named as

Judith M Bliss

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

author name string

Robert E Coleman

1

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

Linda M Banks

2

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

Samia I Girgis

3

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

Lucy S Kilburn

4

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

Eduard Vrdoljak

5

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

John Fox

6

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

Simon J Cawthorn

7

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

Ashraf Patel

8

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

Claire F Snowdon

9

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

R Charles Coombes

12

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

Intergroup Exemestane Study group

13

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

publication date

1 February 2007

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

8

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

2

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

119-127

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone loss and the aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

International variations in hip fracture probabilities: implications for risk assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970003-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(07)70003-7

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17267326

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53579533&oldid=1956443402"